Drug Trial Radar · NCT00202644
A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients
Last checked: Nov 20, 2026Latest source record: Jun 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
150
Actual
Start
Jan 13, 2006
Primary completion
Dec 15, 2015
Study completion Dec 15, 2015
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Sep 20, 2005
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Essential thrombocythaemia is a disorder of bone marrow, which causes too many platelets to be produced. Platelets are small cells carried around in the blood, which help form blood clots. When patients have too many platelets, there is a risk of blood clots forming unnecessarily and excessive bleeding. The aim of this study is to gain additional information on the safety profile of Anagrelide (Xagrid(r)) and Hydroxyurea (also known as hydroxycarbamide).
Conditions
- Thrombocythemia, Hemorrhagic
Interventions
AnagrelideDrug
Anagrelide hydrochloride 0.5mg capsules;initial dose administered will be 1.0mg/day administered as 0.5mg bid. The dose will be titrated such that the total daily dose is incremented by no more than 0.5mg per week as required depending on platelet reduction versus adverse event profile.
HydroxyureaDrug
Hydroxyurea is 500mg hydroxycarbamide capsules; initial dose is 1000mg/day, administered in two divided doses (500mg/dose). Dose titrated to effect to achieve a response.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Left Ventricular Ejection Fraction (LVEF) Over TimeTime frame: Baseline and Month 1, 2, 3, 6, 9, 12, 18, 24, 30 and 36
- Platelet Count at Month 6Time frame: Month 6
Locations
15 sites in 6 countries. Site status is shown where the registry gives one.
University Multiprofile Hospital for Active Treatment ''Dr Georgi Stranski'' - Pleven
Pleven, Bulgaria
University Multiprofile Hospital for active Treatment ''Alexandrovska'' Clinic of Haematology
Sofia, Bulgaria
University Multiprofile Hospital for Active Treament ''Sv. Marina'' - Varna Haematology Clinic
Varna, Bulgaria
Hopital Saint Louis - Centre d'Investigation Clinique
Paris, France
CHU Angers Services des Maladies du Sang
Angers, Cedex 09, France
University of Debrecen Medical and Health Science Centre
Debrecen, Hungary
Petz Aladar County Teaching Hospital
Győr, Hungary
Pandy Kalman Hospital of Bekes County
Gyula, Hungary
Kaposi Mor Teaching Hospital
Kaposvár, Hungary
Uniwersyteckie Centrum Kliniczne Katedra i Klinika Hematologii i Transplantologii
Gdansk, Poland
Samodzielny Publiczny Szpital Kliniczny Nr 1
Lublin, Poland
Katedra i Klinika Onkologii i Chorob Wewnetrznych Akademii Medycznej
Warsaw, Poland
Klinika Hematologii Instytut Hematologii i Transfuzjologi
Warsaw, Poland
Hospitals da Universidade de Coimbra
Coimbra, Portugal
Institute for Haematology of Clinical Centre of Serbia
Belgrade, Serbia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.